Physician profile
Omar E Hanuch
NPI 1316929334
$4,199.11
in general payments reported to CMS, 2019-2025
22 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $305 · 2021: $635 · 2022: $393 · 2023: $597 · 2024: $1,029 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,513.63 | 2020-2025 | Clareon, Hydrus Microstent, Centurion |
| Sight Sciences, INC. | $485.04 | 2019-2025 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $450.26 | 2019-2025 | Tecnis Simplicity, Veritas Vision System |
| Sun Pharmaceutical Industries INC. | $365.31 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $271.17 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Abbvie INC. | $153.80 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $146.58 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $131.11 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $102.90 | 2019-2021 | |
| Oyster Point Pharma, INC. | $85.07 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rxsight INC | $77.78 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Astellas Pharma US INC | $65.85 | 2024 | Izervay |
| Kala Pharmaceuticals, INC. | $59.90 | 2020-2021 | |
| Biotissue Holdings INC. | $59.21 | 2024-2025 | |
| Thea Pharma INC. | $46.46 | 2023-2024 | Iyuzeh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.81 | 2019 | |
| Allergan, INC. | $36.73 | 2020-2021 | |
| Ivantis, INC | $26.32 | 2020-2021 | |
| Genentech USA, INC. | $24.48 | 2024 | Vabysmo |
| Alcon Research LLC | $21.31 | 2019 | |
| Ani Pharmaceuticals, INC. | $19.77 | 2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $19.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Hanuch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.